The FDA is urged to collaborate with relevant payers to reclassify transdermal dietary supplement patches as unapproved drug products, prompting potential recalls for noncompliant items. This shift is crucial as it addresses the significant regulatory risks associated with 24 patch products and GLP-1 patches that currently fall outside legal supplement channels, exposing both manufacturers and users to safety liabilities. As the demand for alternative obesity therapies grows, ongoing legal ambiguities complicate the landscape, necessitating immediate guidance and action.
Title not available for this citation.
“BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials.”
Title not available for this citation.
“TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models, but human orthopaedic data are lacking.”
Title not available for this citation.
“CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss.”
Title not available for this citation.
“Tesamorelin, approved for treating HIV-associated lipodystrophy, has no supporting orthopaedic evidence.”
Title not available for this citation.
“GHK-Cu showed promise in wound healing and anti-inflammatory effects, but no clinical data support its use for musculoskeletal conditions.”
Title not available for this citation.
“Sunless tanners offer a safer alternative to ultraviolet (UV)-based tanning but may cause adverse skin reactions, including irritant and allergic contact dermatitis.”
Title not available for this citation.
“DHA remains the predominant active ingredient, with erythrulose, melanin, and tyrosine derivatives used less frequently.”
Title not available for this citation.
“While sunless tanners provide a UV-free tanning option, dermatologists should educate patients on ingredient safety, potential adverse effects, and proper application techniques.”
Title not available for this citation.
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become an important therapeutic option for metabolic disorders.”
Title not available for this citation.
“Their development, from the early identification of exendin-4 in Gila-monster venom to the creation of long-acting analogues and the first oral peptide, marks a significant step in translational drug design.”
Title not available for this citation.
“This review integrates molecular evolution, formulation advances, and biopharmaceutics modeling, including physiologically based biopharmaceutics modeling (PBBM), to illustrate emerging strategies shaping next-generation oral peptide therapeutics.”
Title not available for this citation.
“Obesity is a chronic, multifactorial disease associated with significant metabolic, physical, and psychosocial complications.”
